Aurobindo Pharma announced that the US Food and Drug Administration (USFDA) completed its inspection of Unit-VI, an API manufacturing facility of Apitoria Pharma, a wholly owned subsidiary, located at E-Bonangi Village, Parawada Mandal, Anakapalli District, Andhra Pradesh from August 24-28, 2026. The inspection concluded with three observations, which are procedural in nature, according to the company's latest announcement. As per CNBC TV18, the company described all three observations as "procedural in nature" and committed to responding to the USFDA within the stipulated timeline. This latest inspection adds to the company's ongoing regulatory scrutiny across multiple facilities, following previous inspections at AuroPeptides and Lannett Company LLC facilities. The company has committed to responding to the USFDA within the stipulated timeline and remains focused on maintaining robust quality and compliance standards across its manufacturing facilities.
Aurobindo Pharma shares gained 0.92% on Friday, August 28, closing at ₹1,652, gaining ₹15 during the session, according to CNBC TV18. The stock has demonstrated strong momentum with a 36% rally in 2026 and a 59% gain over the past year, while delivering a 6.16% return in the past month. The company currently trades at a price-to-earnings multiple of 25.14 times with a market capitalization of ₹93,729.06 crore. The positive market reaction reflects investor confidence in the company's regulatory response and ongoing business operations, despite the ongoing USFDA inspection process. An FDA observation at the end of an inspection identifies conditions that inspectors believe may violate regulatory requirements, but it doesn't by itself amount to a final regulatory action, and companies are typically given an opportunity to respond with corrective measures.
Aurobindo Pharma's shares are expected to remain in focus following the company's receipt of multiple observations from the US Food and Drug Administration (USFDA) across its subsidiaries. The USFDA conducted routine inspections at two of the company's facilities - AuroPeptides, the company's arm manufacturing Peptide APIs, located in Telangana between August 17-21, 2026, and its wholly owned step-down subsidiary Lannett Company LLC's manufacturing facility in Seymour, USA, during the same period. The Telangana facility inspection concluded with one observation relating to facility and equipment maintenance, which the company emphasized does not pertain to data integrity or related GMP compliance. However, the US subsidiary inspection resulted in four observations, indicating more comprehensive regulatory concerns at this facility. The latest inspection of Unit-VI, completed on August 28, 2026, also concluded with three observations, which are procedural in nature. Together, the two inspections have resulted in four observations across two Aurobindo Pharma subsidiaries in the space of a week.
As reported by the company, corrective action was already initiated during the course of the inspection, and formal responses will be submitted within the stipulated timelines for both facilities. AuroPeptides has started corrective action and will submit its formal response to the USFDA within the required timeline, with the company committing to update stock exchanges on any further developments. This proactive approach demonstrates the company's commitment to addressing regulatory concerns promptly. The observations represent routine regulatory matters rather than more serious compliance issues, as confirmed by the company's management. The company didn't disclose further details about the observations, but emphasized its commitment to maintaining quality and compliance standards across its manufacturing facilities.
Despite regulatory concerns, Aurobindo Pharma demonstrated robust financial performance in Q1FY27. As reported, the company achieved a 25.2% year-on-year increase in net profit to ₹1,032 crore compared with ₹824 crore in the previous year. Revenue grew 16.3% year-on-year to ₹9,150.3 crore from ₹7,868 crore, surpassing the CNBC-TV18 poll estimate of ₹9,030 crore. EBITDA increased 17.3% year-on-year to ₹1,881 crore from ₹1,603 crore, ahead of the CNBC-TV18 poll estimate of ₹1,848 crore, with EBITDA margin improving to 21% from 20% year-on-year. The strong financial results provide a positive backdrop against the regulatory developments.
